175 related articles for article (PubMed ID: 12687029)
1. Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children.
Lyttle B; Gilles J; Panov M; Emeryk A; Wixon C
Can Respir J; 2003 Mar; 10(2):103-9. PubMed ID: 12687029
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG; Millar AB; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
Perruchoud AP; Lundback B; Yigla M; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma.
Aubier M; Wettenger R; Gans SJ
Respir Med; 2001 Mar; 95(3):212-20. PubMed ID: 11266239
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma.
Farmer IS; Middle M; Savic J; Perri VL; Herdman MJ
Respir Med; 2000 Jan; 94(1):57-63. PubMed ID: 10714480
[TBL] [Abstract][Full Text] [Related]
8. Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics.
Anderson PB; Langley SJ; Mooney P; Jones J; Addlestone R; Rossetti A; Cantini L
J Investig Allergol Clin Immunol; 2002; 12(2):107-13. PubMed ID: 12371526
[TBL] [Abstract][Full Text] [Related]
9. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.
Bateman ED; Silins V; Bogolubov M
Respir Med; 2001 Feb; 95(2):136-46. PubMed ID: 11217910
[TBL] [Abstract][Full Text] [Related]
10. Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness.
Langley SJ; Holden J; Derham A; Hedgeland P; Sharma RK; Woodcock A
Chest; 2002 Sep; 122(3):806-11. PubMed ID: 12226017
[TBL] [Abstract][Full Text] [Related]
11. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant.
Woodcock A; Williams A; Batty L; Masterson C; Rossetti A; Cantini L
J Aerosol Med; 2002; 15(4):407-14. PubMed ID: 12581507
[TBL] [Abstract][Full Text] [Related]
12. Equivalence of salbutamol 200 microg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Eastern European study group.
Salat D; Popov D; Sykes AP
Respir Med; 2000 Jun; 94 Suppl B():S22-8. PubMed ID: 10919682
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
Fireman P; Prenner BM; Vincken W; Demedts M; Mol SJ; Cohen RM
Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC.
Vastagh E; Kuna P; Calistruc P; Bogdan MA;
Respir Med; 2003 Nov; 97 Suppl D():S20-8. PubMed ID: 14753248
[TBL] [Abstract][Full Text] [Related]
16. Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses.
Grzelewska-Rzymowska I; Malolepszy J; de Molina M; Sladek K; Zarkovice J; Siergiejko Z;
Respir Med; 2003 Nov; 97 Suppl D():S10-9. PubMed ID: 14753247
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A
Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment.
Nelson HS; Wolfe JD; Gross G; Greos LS; Baitinger L; Scott C; Dorinsky P
Ann Allergy Asthma Immunol; 2003 Sep; 91(3):263-9. PubMed ID: 14533658
[TBL] [Abstract][Full Text] [Related]
19. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Fowler SJ; Currie GP; Lipworth BJ
J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical transition to non-CFC pressurized metered dose inhalers.
Cripps A; Riebe M; Schulze M; Woodhouse R
Respir Med; 2000 Jun; 94 Suppl B():S3-9. PubMed ID: 10919679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
